Abstract
In France, efficiency of each new eligible treatment compared to standard therapeutic strategies is evaluated before market launch, but rarely after. If immunotherapies have considerably changed the advanced cancer treatment landscape, few information is available on survival benefits at the population level. The objective was to retrospectively evaluate the public health impact of immunotherapies compared to their comparators.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
